Nanosphere chief commercial officer Michael McGarrity said Thermo Fisher’s marketing, distribution and customer support expertise combined with the ability of Nanosphere’s Verigene system to detect multiple targets in a single, automated test creates a competitive advantage in building a major presence in Germany, Austria and France markets.

Thermo Fisher microbiology European vice president and general manager Paul James said the agreement will focus on Verigene products that provide rapid identification of infectious diseases and associated drug resistance, arming physicians and hospitals with clinically actionable results that improve patient care and reduce the cost of treating critical illnesses.

"Together with our existing range of Thermo Scientific microbiology products, they provide a comprehensive solution to diagnosis of serious infectious disease," James added.

Nanosphere said its Verigene system has received CE mark approval.